Clinical trials: Refractory Autoimmune Diseases
Systemic Lupus Erythematosus
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Systemic lupus erythematosus.
- Trial name
- NCT06920433
- Testing
- UCAR T-cell group
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Autoimmune Encephalopathy
Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients
Investigation of efficacy of vigabatrin in refractory autoimmune encephalitis patients
- Trial name
- NCT03003143
- Testing
- Vigabatrin 500 MG
- Where
- South Korea
- Sponsor
- Seoul National University Hospital
Immune Thrombocytopenia (ITP)
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells(QT-019C) in Patients With Refractory Primary Immune Thrombocytopenia.
- Trial name
- NCT07416032
- Testing
- QT-019C
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Systemic Lupus Erythematosus (SLE)
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
This study is a single arm, open, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SLE.
- Trial name
- NCT07339332
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Neurological Autoimmune Diseases
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY001N cell injection in the treatment of patients with relapsed/refractory…
- Trial name
- NCT07265206
- Testing
- HY001N cell injection
- Volunteers
- 15 people
- Sponsor
- Juventas Cell Therapy Ltd.
Autoimmune Diseases
A Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases
A single arm, open-label pilot study is designed to determine the safety and effectiveness of CAR NK cells in patients with relapsed/refractory B-cell related autoimmune diseases.15 patients are planned to be enrolled in the…
- Trial name
- NCT06318533
- Testing
- CAR NK cells
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- YANRU WANG
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs)
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically…
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
- Trial name
- NCT06991114
- Testing
- Allogeneic NK Cells
- Where
- 52 sites in United States, Brazil and 9 more
- Volunteers
- 90 people
- Sponsor
- Artiva Biotherapeutics, Inc.
Eosinophilic Granulomatosis With Polyangiitis
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
- Trial name
- OCEAN (NCT05263934)
- Testing
- Depemokimab, Mepolizumab
- Where
- 63 sites in United States, Argentina and 16 more
- Volunteers
- 163 people
- Sponsor
- GlaxoSmithKline
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia.
- Conditions
- Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
- Trial name
- NCT01933035
- Testing
- Immune Thrombocytopenics, Hypo-proliferative thrombocytopenics, Control Population
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Beth Israel Medical Center
Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with relapsed and/or refractory SLE.
- Trial name
- NCT05474885
- Testing
- BCMA-CD19 cCAR T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- iCell Gene Therapeutics
Autoimmune Disease
Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
This study is a single center, open label exploratory clinical trial aimed at evaluating the safety and efficacy of autologous CD19 CAR-T therapy in subjects with autoimmune diseases.
- Trial name
- NCT06993493
- Testing
- CD19 CART
- Where
- China
- Sponsor
- Beijing Boren Hospital
Refractory Myasthenia Gravis
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
This is an open label, single arm study, to evaluate the safety , tolerability and preliminary efficacy of HN2302 for refractory myasthenia gravis.
- Trial name
- NCT07413835
- Testing
- HN2302 Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
The purpose of this study is to evaluate the safety and efficacy of sirukumab as a single therapy in Japanese patients with moderately to severely active rheumatoid arthritis (RA) who have not responded to treatment with…
- Trial name
- NCT01689532
- Testing
- Sirukumab 100 mg, Sirukumab 50 mg
- Where
- 17 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Janssen Pharmaceutical K.K.
Autoimmune Diseases Refractory to Standard Therapies
RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies
This is a open-label, exploratory trial to evaluate the safety, feasibility, and preliminary efficacy of RN1201, an Allogeneic CAR-T cell therapy, in patients with autoimmune diseases refractory to standard treatment.
- Trial name
- NCT07105735
- Testing
- allogeneic CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Moderate to Severe Refractory Autoimmune Diseases
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases
This study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the safety, efficacy and cellular pharmacokinetics of GT801 injection in patients with moderate to severe refractory…
- Trial name
- NCT07614191
- Testing
- GT801 Injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Vivacta Biotechnology (Shanghai) Co., Ltd.
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP
This is a multicenter, open-label, single-dose, dose-escalation study evaluating the safety and tolerability of intravenous (IV) KINE-101 in patients with corticosteroid-refractory chronic inflammatory demyelinating…
- Trial name
- NCT07343310
- Testing
- KINE-101
- Where
- 2 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- Kine Sciences Co., Ltd.
Immune Thrombocytopenia
The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and ATRA in patients with steroid-resistant/relapsed ITP.
- Trial name
- NCT03304288
- Testing
- Rituximab, All-trans retinoic acid
- Where
- 4 sites in China
- Volunteers
- 168 people
- Sponsor
- Peking University People's Hospital
Systemic Lupus Erythematosus
Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus
This is an investigator-initiated trial to evaluate the safety and efficacy of CD19 Universal CAR-T cells in the treatment of refractory systemic lupus erythematosus.
- Trial name
- SLE (NCT06691152)
- Testing
- CD19 Universal CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Refractory Lupus Nephritis, Systemic Sclerosis
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), primary Sjogren syndrome combined with pulmonary artery hypertension…
- Conditions
- Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, Other Autoimmune Diseases (AID)
- Trial name
- NCT06947460
- Testing
- CD19-BCMA CAR-T cells infusion
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing GoBroad Hospital
Scleroderma, Autoimmune Diseases
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
- Trial name
- NCT05085444
- Testing
- Assigned Interventions CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University